Lean mass loss remains a legitimate clinical concern for specific subpopulations — particularly older adults who already lose approximately 8% lean mass per decade after age 40, those with frailty, and those at risk for low bone mineral density — where GLP-1 therapy may accelerate age-related sarcopenia.

Evidence (1)

Muscle Matters: The Challenge of Preserving Lean Mass During Obesity Treatment

Older adults, frail patients, and those at risk for low bone mineral density identified as populations at greater risk for clinically meaningful lean mass loss.

https://www.healio.com/news/endocrinology/20251114/muscle-matters-the-challenge-of-preserving-lean-mass-during-obesity-treatment

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/693262ac8029f1a05846f32bc16d93425875facedae568164c6414f266a8d6c8"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.